Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Amyloidosis: early-phase trial registry
15 of 29 indexed Amyloidosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 15 currently recruiting · #552 of 28,707 conditions by registered trial count
Amyloidosis: 29 US clinical trials tracked, 15 recruiting.
Amyloidosis is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 6 of these trials.
Enrollment posture brief
Registry condition amyloidosis
OPEN 15 | RECR 52% | LATE 3 | EARLY 11 | RANK #552 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Kidney Stone (52% recruiting · 29 trials)
Amyloidosis lists 15 open slots (52% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Amyloidosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Amyloidosis is recruiting above its size-band peers.
15 of 29 indexed trials (51.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Amyloidosis research.
Mayo Clinic accounts for 6 of 29 trials (20.7%). 21 distinct sponsors appear on at least one study for this condition label.
-
Typical Amyloidosis enrolment sits around 87 participants.
Median target enrolment is 87 among the 29 trials that report a genuine target (sentinel values excluded). 16 of those (55.2%) plan for fewer than 100 participants.
-
Amyloidosis splits between interventional and observational designs.
18 interventional and 11 observational studies make up this index (62.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
NCT05635266
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
University of Alabama at Birmingham
NCT05556928
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
NCT03717844
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
xCures
NCT06539169
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
NCT06563895
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Massachusetts General Hospital
NCT05577819
A Study Of MCG In Cardiac Amyloidosis
Mayo Clinic
NCT07218705
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Oregon Health and Science University
NCT05758493
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Alexion Pharmaceuticals
NCT07081646
Dietary Reporting in the Amyloidoses
Barbara Ann Karmanos Cancer Institute
NCT05738005
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
NCT04991103
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
NCT05145816
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06974877
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT07285044
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
Mayo Clinic
NCT07216469
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Janssen Research & Development
NCT05250973
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Memorial Sloan Kettering Cancer Center
NCT02909036
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
Mayo Clinic
NCT03584022
Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation
Mayo Clinic
NCT01606280
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
C.T. Development America
NCT01215747
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Alnylam Pharmaceuticals
NCT02510261
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
The Cleveland Clinic
NCT03923920
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
NCT01864018
Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
Tufts Medical Center
NCT02555969
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
The Cleveland Clinic
NCT03431896
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
NCT01083316
Ixazomib Rollover Study
Takeda
NCT02924272
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
NCT01383759
Evaluation of MyoStrain™ in Clinical Practice
University of Kansas Medical Center
NCT03825224
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 6 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Amyloidosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Amyloidosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Amyloidosis page
29 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Amyloidosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Amyloidosis trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Amyloidosis condition card totals 29 registered trials; most-linked intervention Dexamethasone; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.